Navigation Links
Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts
Date:12/1/2011

s that may significantly interact with GLEEVEC include acetaminophen, warfarin, erythromycin, and metoprolol.  Grapefruit juice should also be avoided in patients taking GLEEVEC. (Please see full Prescribing Information for other potential drug interactions).

Patients with moderate renal impairment (CrCL = 20-39 mL/min) should receive a 50% decrease in the recommended starting dose and future doses can be increased as tolerated. Doses greater than 600 mg are not recommended in patients with mild renal impairment (CrCL = 40-59 mL/min). For patients with moderate renal impairment, doses greater than 400 mg are not recommended. GLEEVEC should be used with caution in patients with severe renal impairment.

Common Side Effects of GLEEVEC Tablets

Almost all adult Ph+ CML patients who received GLEEVEC in clinical studies experienced adverse reactions at some time, but most were mild to moderate in severity. The most frequently reported adverse reactions (all Grades) were superficial edema (60%-74%), nausea (50%-73%), diarrhea (43%-57%), musculoskeletal pain (38%-49%), rash and related terms (36%-47%), muscle cramps (28%-62%), and vomiting (23%-58%)(+).

Supportive care may help reduce the severity of some mild-to-moderate adverse reactions. However, in some cases, either a dose reduction or interruption of treatment with GLEEVEC may be necessary.

For daily dosing of 800 mg and above, dosing should be accomplished using the 400-mg tablet to reduce exposure to iron.

GLEEVEC tablets should be taken with food and a large glass of water to minimize GI irritation.

Patients should be informed to take GLEEVEC exactly as prescribed, and not to change their dose or stop taking GLEEVEC unless they are told to do so by their doctor. If patients miss a dose, they should be advised to take their dose as soon as possible unless it is almost time for their next dose, in which case the missed dose should not be taken. A double dose should
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Related biology technology :

1. Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis
2. Genentech and Novartis Remain Image Leaders in Oncology and Hematology
3. FDA Advisory Committee Recommends US Approval of Novartis Once-daily Bronchodilator QAB149 for COPD
4. Novartis Drug Afinitor® Extends Progression-Free Survival in Patients With Advanced Pancreatic NET, Study Published in NEJM Shows
5. With the Recent Launch of Novartiss Gilenya, Extavia is Pushed Into the Background of Multiple Sclerosis Treatment One Year After its Launch
6. VIDEO from Novartis Available on thenewsmarket.com: Novartis Presents Data about Tasigna in Treatment of Patients with Newly Diagnosed Ph+ Chronic Myeloid Leukemia
7. Drug Sales in the Leukemia Market Will Be Driven By Therapies From Novartis, Bristol-Myers Squibb, Biogen Idec, Roche and Cephalon
8. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
9. Novartis Class Awarded $250 Million in Punitive Damages
10. Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR(TM) Technology and Generate Novel Drug Leads Against a GPCR Target
11. Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... 2015  MiMedx Group, Inc. (NASDAQ: MDXG ), ... and patent-protected processes to develop and market advanced products ... Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced ... Annual Canaccord|Genuity Growth Conference in Boston, ... CEO, William C. Taylor , President and COO, ...
(Date:8/3/2015)... , August 3, 2015 E-QURE ... commercialization of its Bio-electrical Signal Therapy device ("BST Device"), ... of hard to heal chronic wounds, today announced that ... Chemipal, an Israeli distributor specializing in medical devices, for ... Chemipal is a 70 years old, sales, marketing ...
(Date:7/31/2015)... July 31, 2015 In today,s fast ... help them drive positive health outcomes, improve profitability ... of patient care in their communities. At ThoughtSpot ... and conference, AmerisourceBergen announced a new set of ... Administration Organization and help independent pharmacies endure the ...
(Date:7/30/2015)... AACC welcomed thousands of medical professionals ... Meeting & Clinical Lab Expo in ... showcased revolutionary advancements in clinical testing technology and ... to diagnose patients quickly and accurately and make ... As of Wednesday, July 29, more than ...
Breaking Biology Technology:MiMedx To Present At 35th Annual Canaccord|Genuity Growth Conference 2E-QURE Corp Signs Second Distribution Agreement in Israel 2E-QURE Corp Signs Second Distribution Agreement in Israel 3AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 2AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4
... PRXL ) announced today that it will ... Palos Verdes, California.  James Winschel, Sr. Vice President and ... on Wednesday, June 6, 2012. PAREXEL will ... New York.  Josef von Rickenbach, Chairman and Chief Executive ...
... Calif., May 23, 2012  Cepheid (NASDAQ: CPHD ... CT have received CE marking, with shipments expected to ... are qualitative in vitro molecular diagnostic tests ... trachomatis (CT) and Neisseria gonorrhoeae (NG). ...
... This press release is available in German ... is intended to bring to an end to the confusing mishmash ... any rate, is Harald Krug,s assessment of the situation. Krug is ... specialist. In the past few years the number of publications on ...
Cached Biology Technology:PAREXEL International To Present At Goldman Sachs Healthcare Conference And Jefferies Healthcare Conference 2Cepheid Announces European Release of Xpert CT/NG and Xpert CT, Delivering Rapid Detection and Differentiation of Chlamydia and Gonorrhoeae 2Cepheid Announces European Release of Xpert CT/NG and Xpert CT, Delivering Rapid Detection and Differentiation of Chlamydia and Gonorrhoeae 3Cepheid Announces European Release of Xpert CT/NG and Xpert CT, Delivering Rapid Detection and Differentiation of Chlamydia and Gonorrhoeae 4A milestone in nanoparticle research: Nanoparticle test handbook sets the standards 2
(Date:7/31/2015)... SHENZHEN, China , 31. Juli 2015 Die ... ) wird von BGI veranstaltet und findet vom ... Shenzhen, China , statt. ... Jubiläum. Seit ihrem Start 2006 ist die ICG ... Bereich „omik" geworden. Sie ist eines der dynamischsten, ...
(Date:7/31/2015)... China , July 31, 2015 The 10 ... will be held by BGI from October 22-25, 2015, in ... The conference is celebrating its 10 th anniversary ... one of the world,s most influential annual meetings in the ... and enjoyable scientific gatherings. ICG-10 focuses on ...
(Date:7/27/2015)... July 27, 2015  Synaptics Inc. (NASDAQ: ... solutions, today announced that Huawei has selected the ... for its stylish smartwatch. Huawei chose the state-of-the-art ... low power and highly responsive human interface qualities ... designers also required a classic round watch face ...
Breaking Biology News(10 mins):Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 2Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 3The 10th International Conference on Genomics (ICG-10) to Open in October 2Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3
... North Atlantic right whales have been seen in the ... researchers at NOAA,s Northeast Fisheries Science Center (NEFSC) to ... a breeding ground for this endangered species. The ... on December 3 in the Jordan Basin area, located ...
... Hopkins neuroscientists has worked out how some newly discovered ... with the brain. The report appears online this week ... are a small number of nerve cells in the ... in the retinarods and conesmelanopsin-containing cells are not used ...
... NEW YORK (DECEMBER 30, 2008)The Bronx Zoo-based Wildlife Conservation Society ... region in South America have paid off in the form ... by the Government of Argentina. ... which became official earlier this month, protects half a million ...
Cached Biology News:High numbers of right whales seen in Gulf of Maine 2High numbers of right whales seen in Gulf of Maine 3High numbers of right whales seen in Gulf of Maine 4Bright lights, not-so-big pupils 2Bright lights, not-so-big pupils 3A happy new year for penguins 2
Nestin, Human...
Ezrin/Radixin/Moesin Antibody...
... polyclonal to Taura Syndrome Virus ... for all tested applications). ... peptide: VTNSEGSTIL MNDIPITNQN VVLSKNVTDN LFEVQDQALI ... to N terminal amino acids ...
JAB1 Immunogen: Synthetic peptide, conjugated to KLH, corresponding to residues S(201) E Y Q T I P L N K I E D F G V(216) of human JAB1. The sequence is identical in mouse and rat. Storage: -...
Biology Products: